PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Xellia Pharmaceuticals Aps

USPTO PatentsView assignee record - 27 granted patents across 16 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Explore the portfolio See the ranking
27
Total patents granted
16
CPC technology areas
16.2
Avg claims per patent
+25%
5-year grant velocity

The verdict

According to USPTO PatentsView, Xellia ranks #11,518 of 50,000 tracked US assignees by granted-patent volume, with 27 patents across 16 technology areas.

#11,518
of 50,000 US assignees by volume
Top 41%
by Innovation Score (38.5/100)
16.2
avg claims per patent
+25%
grant velocity, last 5 yrs

Portfolio overview

Xellia Pharmaceuticals Aps has been granted 27 US utility patents between 2015 and 2024, placing Xellia Pharmaceuticals Aps at #11,518 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 16 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.2 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Xellia Pharmaceuticals Aps is one of the more focused assignees in the PatentsView dataset. By volume, Xellia sits between Wave Computing, Inc. (27 patents, rank #11,510) and Zapadoceska Univerzita V Plzni (27 patents, rank #11,518) - the closest US assignees by grant volume. The composite Innovation Score of 38.5/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 15 grants, compared with 12 in the 2015–2019 window, a +25% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Xellia Pharmaceuticals Aps's 16.2 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 16 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Xellia's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Xellia holds 27 patents at rank #11,514, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Xellia

By rank, the assignees closest to #11,514 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Xellia's primary technology class.

Xellia's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 41% higher than 59% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0123456 201520162018201920202021202220232024 3
USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Xellia Pharmaceuticals Aps patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 5 18.5%
2016 2 7.4%
2018 1 3.7%
2019 4 14.8%
2020 5 18.5%
2021 4 14.8%
2022 1 3.7%
2023 2 7.4%
2024 3 11.1%

Which technologies does Xellia Pharmaceuticals Aps patent most?

Top 15 of 16 technology areas

Grant record at a glance

Portfolio Volume 27 grants
CPC subclasses 16
Avg. claims / grant 16.2
Velocity +25%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#11,518

of 50,000 tracked assignees

Innovation Score

38.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Xellia Pharmaceuticals Aps rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Xellia Pharmaceuticals Aps ranks #11,518 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Xellia Pharmaceuticals Aps hold?
Xellia Pharmaceuticals Aps holds 27 US utility patents granted between 2015 and 2024, spanning 16 technology areas.
What is Xellia Pharmaceuticals Aps's Innovation Score?
Xellia Pharmaceuticals Aps has an Innovation Score of 38.5 out of 100 (top 41% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Xellia Pharmaceuticals Aps focus on?
Xellia Pharmaceuticals Aps's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 21 patents. Grants appear in 16 CPC subclasses total.
Is Xellia Pharmaceuticals Aps's patent grant rate increasing or decreasing?
Xellia Pharmaceuticals Aps's recent grant velocity is +25% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.
What does claim depth mean for Xellia Pharmaceuticals Aps's patents?
Xellia Pharmaceuticals Aps's patents average 16.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Xellia Pharmaceuticals Aps patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Xellia's 27 grants land it in the top 41% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Xellia ranks #11,518 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.